Testosterone Blocker - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB510243220

Publication Date:

October 2, 2024

Pages:

107

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Testosterone blockers, also known as anti-androgen drugs, are used to block the masculinizing effects of testosterone in transgender women. Aldactone (spironolactone) is most commonly used, but other drugs like Propecia (finasteride), Avodart (dutasteride), and Eulexin (flutamide) may also be prescribed.
The global market for Testosterone Blocker was estimated to be worth US$ 3260 million in 2023 and is forecast to a readjusted size of US$ 4676.4 million by 2030 with a CAGR of 5.2% during the forecast period 2024-2030
Drivers of the Testosterone Blocker 麻豆原创
Increasing prevalence of prostate cancer: Prostate cancer is the most common cancer among men in the United States. Testosterone is a key driver of prostate cancer growth, and testosterone blockers are used to treat the disease.
Rising transgender population: The transgender population is growing rapidly, and testosterone blockers are used to help transgender individuals transition from male to female.
Female hirsutism: Hirsutism is a condition in which women have excessive hair growth on their face, chest, and back. Testosterone blockers can be used to treat hirsutism.
Challenges to the Testosterone Blocker 麻豆原创
Side effects: Testosterone blockers can have a number of side effects, including hot flashes, fatigue, weight gain, and mood swings. These side effects can discourage some people from using testosterone blockers.
Cost: Testosterone blockers can be expensive, and insurance coverage for these drugs is not always available.
Regulatory hurdles: Testosterone blockers are regulated by the FDA, and the approval process for new drugs can be lengthy and expensive.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Testosterone Blocker, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Testosterone Blocker by region & country, by Type, and by Application.
The Testosterone Blocker market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Testosterone Blocker.
麻豆原创 Segmentation
By Company
Pfizer
Johnson & Johnson
AstraZeneca
Astellas
Merck
Sanofi
Orion Corporation
Hengrui
Bayer
Schering-Plough
Hinova Pharma
Jiangsu Hengrui Pharmaceuticals
Segment by Type:
Steroidal Testosterone Blocker
Nonsteroidal Testosterone Blocker
Segment by Application
Prostate Cancer
Benign Prostatic Hyperplasia
Polycystic Ovary Syndrome (POCS)
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Testosterone Blocker manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Testosterone Blocker in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Testosterone Blocker in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Testosterone Blocker Product Introduction
1.2 Global Testosterone Blocker 麻豆原创 Size Forecast
1.3 Testosterone Blocker 麻豆原创 Trends & Drivers
1.3.1 Testosterone Blocker Industry Trends
1.3.2 Testosterone Blocker 麻豆原创 Drivers & Opportunity
1.3.3 Testosterone Blocker 麻豆原创 Challenges
1.3.4 Testosterone Blocker 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Testosterone Blocker Players Revenue Ranking (2023)
2.2 Global Testosterone Blocker Revenue by Company (2019-2024)
2.3 Key Companies Testosterone Blocker Manufacturing Base Distribution and Headquarters
2.4 Key Companies Testosterone Blocker Product Offered
2.5 Key Companies Time to Begin Mass Production of Testosterone Blocker
2.6 Testosterone Blocker 麻豆原创 Competitive Analysis
2.6.1 Testosterone Blocker 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Testosterone Blocker Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Testosterone Blocker as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Steroidal Testosterone Blocker
3.1.2 Nonsteroidal Testosterone Blocker
3.2 Global Testosterone Blocker Sales Value by Type
3.2.1 Global Testosterone Blocker Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Testosterone Blocker Sales Value, by Type (2019-2030)
3.2.3 Global Testosterone Blocker Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Prostate Cancer
4.1.2 Benign Prostatic Hyperplasia
4.1.3 Polycystic Ovary Syndrome (POCS)
4.1.4 Others
4.2 Global Testosterone Blocker Sales Value by Application
4.2.1 Global Testosterone Blocker Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Testosterone Blocker Sales Value, by Application (2019-2030)
4.2.3 Global Testosterone Blocker Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Testosterone Blocker Sales Value by Region
5.1.1 Global Testosterone Blocker Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Testosterone Blocker Sales Value by Region (2019-2024)
5.1.3 Global Testosterone Blocker Sales Value by Region (2025-2030)
5.1.4 Global Testosterone Blocker Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Testosterone Blocker Sales Value, 2019-2030
5.2.2 North America Testosterone Blocker Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Testosterone Blocker Sales Value, 2019-2030
5.3.2 Europe Testosterone Blocker Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Testosterone Blocker Sales Value, 2019-2030
5.4.2 Asia Pacific Testosterone Blocker Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Testosterone Blocker Sales Value, 2019-2030
5.5.2 South America Testosterone Blocker Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Testosterone Blocker Sales Value, 2019-2030
5.6.2 Middle East & Africa Testosterone Blocker Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Testosterone Blocker Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Testosterone Blocker Sales Value
6.3 United States
6.3.1 United States Testosterone Blocker Sales Value, 2019-2030
6.3.2 United States Testosterone Blocker Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Testosterone Blocker Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Testosterone Blocker Sales Value, 2019-2030
6.4.2 Europe Testosterone Blocker Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Testosterone Blocker Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Testosterone Blocker Sales Value, 2019-2030
6.5.2 China Testosterone Blocker Sales Value by Type (%), 2023 VS 2030
6.5.3 China Testosterone Blocker Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Testosterone Blocker Sales Value, 2019-2030
6.6.2 Japan Testosterone Blocker Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Testosterone Blocker Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Testosterone Blocker Sales Value, 2019-2030
6.7.2 South Korea Testosterone Blocker Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Testosterone Blocker Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Testosterone Blocker Sales Value, 2019-2030
6.8.2 Southeast Asia Testosterone Blocker Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Testosterone Blocker Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Testosterone Blocker Sales Value, 2019-2030
6.9.2 India Testosterone Blocker Sales Value by Type (%), 2023 VS 2030
6.9.3 India Testosterone Blocker Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Pfizer
7.1.1 Pfizer Profile
7.1.2 Pfizer Main Business
7.1.3 Pfizer Testosterone Blocker Products, Services and Solutions
7.1.4 Pfizer Testosterone Blocker Revenue (US$ Million) & (2019-2024)
7.1.5 Pfizer Recent Developments
7.2 Johnson & Johnson
7.2.1 Johnson & Johnson Profile
7.2.2 Johnson & Johnson Main Business
7.2.3 Johnson & Johnson Testosterone Blocker Products, Services and Solutions
7.2.4 Johnson & Johnson Testosterone Blocker Revenue (US$ Million) & (2019-2024)
7.2.5 Johnson & Johnson Recent Developments
7.3 AstraZeneca
7.3.1 AstraZeneca Profile
7.3.2 AstraZeneca Main Business
7.3.3 AstraZeneca Testosterone Blocker Products, Services and Solutions
7.3.4 AstraZeneca Testosterone Blocker Revenue (US$ Million) & (2019-2024)
7.3.5 Astellas Recent Developments
7.4 Astellas
7.4.1 Astellas Profile
7.4.2 Astellas Main Business
7.4.3 Astellas Testosterone Blocker Products, Services and Solutions
7.4.4 Astellas Testosterone Blocker Revenue (US$ Million) & (2019-2024)
7.4.5 Astellas Recent Developments
7.5 Merck
7.5.1 Merck Profile
7.5.2 Merck Main Business
7.5.3 Merck Testosterone Blocker Products, Services and Solutions
7.5.4 Merck Testosterone Blocker Revenue (US$ Million) & (2019-2024)
7.5.5 Merck Recent Developments
7.6 Sanofi
7.6.1 Sanofi Profile
7.6.2 Sanofi Main Business
7.6.3 Sanofi Testosterone Blocker Products, Services and Solutions
7.6.4 Sanofi Testosterone Blocker Revenue (US$ Million) & (2019-2024)
7.6.5 Sanofi Recent Developments
7.7 Orion Corporation
7.7.1 Orion Corporation Profile
7.7.2 Orion Corporation Main Business
7.7.3 Orion Corporation Testosterone Blocker Products, Services and Solutions
7.7.4 Orion Corporation Testosterone Blocker Revenue (US$ Million) & (2019-2024)
7.7.5 Orion Corporation Recent Developments
7.8 Hengrui
7.8.1 Hengrui Profile
7.8.2 Hengrui Main Business
7.8.3 Hengrui Testosterone Blocker Products, Services and Solutions
7.8.4 Hengrui Testosterone Blocker Revenue (US$ Million) & (2019-2024)
7.8.5 Hengrui Recent Developments
7.9 Bayer
7.9.1 Bayer Profile
7.9.2 Bayer Main Business
7.9.3 Bayer Testosterone Blocker Products, Services and Solutions
7.9.4 Bayer Testosterone Blocker Revenue (US$ Million) & (2019-2024)
7.9.5 Bayer Recent Developments
7.10 Schering-Plough
7.10.1 Schering-Plough Profile
7.10.2 Schering-Plough Main Business
7.10.3 Schering-Plough Testosterone Blocker Products, Services and Solutions
7.10.4 Schering-Plough Testosterone Blocker Revenue (US$ Million) & (2019-2024)
7.10.5 Schering-Plough Recent Developments
7.11 Hinova Pharma
7.11.1 Hinova Pharma Profile
7.11.2 Hinova Pharma Main Business
7.11.3 Hinova Pharma Testosterone Blocker Products, Services and Solutions
7.11.4 Hinova Pharma Testosterone Blocker Revenue (US$ Million) & (2019-2024)
7.11.5 Hinova Pharma Recent Developments
7.12 Jiangsu Hengrui Pharmaceuticals
7.12.1 Jiangsu Hengrui Pharmaceuticals Profile
7.12.2 Jiangsu Hengrui Pharmaceuticals Main Business
7.12.3 Jiangsu Hengrui Pharmaceuticals Testosterone Blocker Products, Services and Solutions
7.12.4 Jiangsu Hengrui Pharmaceuticals Testosterone Blocker Revenue (US$ Million) & (2019-2024)
7.12.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
8 Industry Chain Analysis
8.1 Testosterone Blocker Industrial Chain
8.2 Testosterone Blocker Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Testosterone Blocker Sales Model
8.5.2 Sales Channel
8.5.3 Testosterone Blocker Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Pfizer
Johnson & Johnson
AstraZeneca
Astellas
Merck
Sanofi
Orion Corporation
Hengrui
Bayer
Schering-Plough
Hinova Pharma
Jiangsu Hengrui Pharmaceuticals

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.